In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Valeant buys Dow Pharmaceutical Sciences for $277mm in cash

Executive Summary

Valeant Pharmaceuticals International (mostly neurology and dermatology products) has agreed to acquire privately held topical dermatology therapeutics company Dow Pharmaceutical Sciences in a deal worth $285mm plus earn-outs. Valeant will pay $250mm at closing and fund a $35mm escrow account subject to indemnification claims from Valeant for 18 months after the transaction is completed. In addition, Dow is entitled to $235mm in milestones based on approval and commercial targets for some pipeline projects.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Includes Earnout
    • Intra-Biotech Deal
    • Payment Includes Cash

Related Companies